← Evidence map

ArticleTrials2025

A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial.

Adesola Zaidat Musa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial. | OpenQuestion